Table 2.

Best overall biomarker response in patients with elevated baseline biomarkers.

	Chromogranin A		Plasma total metanephrines		Urine total metanephrines		Plasma normetanephrine		Urine normetanephrine		Plasma metanephrine		Urine metanephrine
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Patients receiving any therapeutic dose of HSA I-131 MIBG
Baseline 1.5× upper limit of normal	49	-	54	-	53	-	56	-	52	-	17	-	16	-
Complete response + partial responses	39	80	37	69	37	70	35	63	34	65	12	71	9	56
Complete response	22	45	6	11	12	23	4	7	10	19	2	12	2	13
Partial response	17	35	31	57	25	47	31	55	24	46	10	59	7	44
Stable disease	8	16	16	30	15	28	20	36	17	33	3	18	7	44
Progressive disease	2	4	1	2	1	2	1	2	1	2	2	12	0	0
Patients receiving two therapeutic doses of HSA I-131 MIBG
Baseline 1.5× upper limit of normal	35	-	40	-	40	-	40	-	38		12	-	13	-
Complete response + partial responses	30	86	31	78	31	78	30	75	28	74	10	83	9	69
Complete response	20	57	4	10	10	25	3	8	7	18	1	8	2	15
Partial response	10	29	27	68	21	53	27	68	21	55	9	75	7	54
Stable disease	5	14	9	23	8	20	10	25	9	24	2	17	4	31
Progressive disease	0	0	0	0	1	3	0	0	1	3	0	0	0	0

HSA I-131 MIBG, high-specific-activity I-131 meta-iodobenzylguanidine.